Darzalex will now be available to patients with newly diagnosed multiple myeloma eligible for autologous stem cell transplant ...

Johnson & Johnson has secured European approval for the subcutaneous formulation of Darzalex, combined with bortezomib, lenalidomide, and dexamethasone, for newly diagnosed multiple myeloma patients ...

Janssen-Cilag’s Darzalex -SC based quadruplet regimen gets European approval to treat patients with newly diagnosed MM who are transplant-eligible: Beerse, Belgium Thursday, Oct ...

Leerink Partners analyst David Risinger maintained a Hold rating on Halozyme (HALO – Research Report) yesterday and set a price target of ...

Analyst Jason Butler from JMP Securities reiterated a Buy rating on Halozyme (HALO – Research Report) and keeping the price target at ...

The original IV version of Darzalex has been a big earner for J&J ever since it was first approved in 2015 as a fourth-line myeloma therapy, growing rapidly on the back of successive approvals in ...

Shares of Genmab A/S (OTCMKTS:GNMSF – Get Free Report) passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $266.48 and traded as low as ...

We recently published a list of 10 Worst Performing Dow Stocks Year-to-Date. In this article, we are going to take a look at ...

The successful development in other MM indications would also help the company compete with J&J JNJ, whose blockbuster anti-CD38 therapy Darzalex is approved for similar use in the MM space. The J&J ...

The UK’s National Institute of Health and Care Excellence (NICE) said the drug provided only a small benefit to patients.